Evidence map›Paper›PMID 26380184›Full record

ArticleTranslational lung cancer research2015

Improving the pathologic evaluation of lung cancer resection specimens.

Raymond U Osarogiagbon, Holly L Hilsenbeck, Elizabeth W Sales, Allen Berry, Robert W Jarrett, Christopher S Giampapa, Clara N Finch-Cruz, David Spencer

Open access · greenAbstract read
In one paragraph

Article in Translational lung cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Raymond U Osarogiagbon1 Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA ; 2 Duckworth Pathology Group, Memphis, TN, USA ; 3 Doctors Anatomic Pathology, Jonesboro, AR, USA ; 4 Department of Pathology, St. Francis Hospital, Memphis, TN, USA ; 5 Pathology and Clinical Laboratories, North Mississippi Medical Center, Tupelo, MS, USA ; 6 Medical Center Laboratory, Jackson-Madison County General Hospital, Jackson, TN, USA ; 7 Pathology and Laboratory Medicine Service, Department of Veterans Affairs, VA Medical Center Memphis, TN, USA ; 8 Trumbull Laboratories, LLC/Pathology Group of the Mid-South, Memphis, TN, USA.
Holly L Hilsenbeck1 Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA ; 2 Duckworth Pathology Group, Memphis, TN, USA ; 3 Doctors Anatomic Pathology, Jonesboro, AR, USA ; 4 Department of Pathology, St. Francis Hospital, Memphis, TN, USA ; 5 Pathology and Clinical Laboratories, North Mississippi Medical Center, Tupelo, MS, USA ; 6 Medical Center Laboratory, Jackson-Madison County General Hospital, Jackson, TN, USA ; 7 Pathology and Laboratory Medicine Service, Department of Veterans Affairs, VA Medical Center Memphis, TN, USA ; 8 Trumbull Laboratories, LLC/Pathology Group of the Mid-South, Memphis, TN, USA.
Elizabeth W Sales1 Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA ; 2 Duckworth Pathology Group, Memphis, TN, USA ; 3 Doctors Anatomic Pathology, Jonesboro, AR, USA ; 4 Department of Pathology, St. Francis Hospital, Memphis, TN, USA ; 5 Pathology and Clinical Laboratories, North Mississippi Medical Center, Tupelo, MS, USA ; 6 Medical Center Laboratory, Jackson-Madison County General Hospital, Jackson, TN, USA ; 7 Pathology and Laboratory Medicine Service, Department of Veterans Affairs, VA Medical Center Memphis, TN, USA ; 8 Trumbull Laboratories, LLC/Pathology Group of the Mid-South, Memphis, TN, USA.
Allen Berry1 Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA ; 2 Duckworth Pathology Group, Memphis, TN, USA ; 3 Doctors Anatomic Pathology, Jonesboro, AR, USA ; 4 Department of Pathology, St. Francis Hospital, Memphis, TN, USA ; 5 Pathology and Clinical Laboratories, North Mississippi Medical Center, Tupelo, MS, USA ; 6 Medical Center Laboratory, Jackson-Madison County General Hospital, Jackson, TN, USA ; 7 Pathology and Laboratory Medicine Service, Department of Veterans Affairs, VA Medical Center Memphis, TN, USA ; 8 Trumbull Laboratories, LLC/Pathology Group of the Mid-South, Memphis, TN, USA.
Robert W Jarrett1 Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA ; 2 Duckworth Pathology Group, Memphis, TN, USA ; 3 Doctors Anatomic Pathology, Jonesboro, AR, USA ; 4 Department of Pathology, St. Francis Hospital, Memphis, TN, USA ; 5 Pathology and Clinical Laboratories, North Mississippi Medical Center, Tupelo, MS, USA ; 6 Medical Center Laboratory, Jackson-Madison County General Hospital, Jackson, TN, USA ; 7 Pathology and Laboratory Medicine Service, Department of Veterans Affairs, VA Medical Center Memphis, TN, USA ; 8 Trumbull Laboratories, LLC/Pathology Group of the Mid-South, Memphis, TN, USA.
Christopher S Giampapa1 Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA ; 2 Duckworth Pathology Group, Memphis, TN, USA ; 3 Doctors Anatomic Pathology, Jonesboro, AR, USA ; 4 Department of Pathology, St. Francis Hospital, Memphis, TN, USA ; 5 Pathology and Clinical Laboratories, North Mississippi Medical Center, Tupelo, MS, USA ; 6 Medical Center Laboratory, Jackson-Madison County General Hospital, Jackson, TN, USA ; 7 Pathology and Laboratory Medicine Service, Department of Veterans Affairs, VA Medical Center Memphis, TN, USA ; 8 Trumbull Laboratories, LLC/Pathology Group of the Mid-South, Memphis, TN, USA.
Clara N Finch-Cruz1 Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA ; 2 Duckworth Pathology Group, Memphis, TN, USA ; 3 Doctors Anatomic Pathology, Jonesboro, AR, USA ; 4 Department of Pathology, St. Francis Hospital, Memphis, TN, USA ; 5 Pathology and Clinical Laboratories, North Mississippi Medical Center, Tupelo, MS, USA ; 6 Medical Center Laboratory, Jackson-Madison County General Hospital, Jackson, TN, USA ; 7 Pathology and Laboratory Medicine Service, Department of Veterans Affairs, VA Medical Center Memphis, TN, USA ; 8 Trumbull Laboratories, LLC/Pathology Group of the Mid-South, Memphis, TN, USA.
David Spencer1 Multidisciplinary Thoracic Oncology Program, Baptist Cancer Center, Memphis, TN, USA ; 2 Duckworth Pathology Group, Memphis, TN, USA ; 3 Doctors Anatomic Pathology, Jonesboro, AR, USA ; 4 Department of Pathology, St. Francis Hospital, Memphis, TN, USA ; 5 Pathology and Clinical Laboratories, North Mississippi Medical Center, Tupelo, MS, USA ; 6 Medical Center Laboratory, Jackson-Madison County General Hospital, Jackson, TN, USA ; 7 Pathology and Laboratory Medicine Service, Department of Veterans Affairs, VA Medical Center Memphis, TN, USA ; 8 Trumbull Laboratories, LLC/Pathology Group of the Mid-South, Memphis, TN, USA.
Memphis VA Medical Center · US

Funding

Improving pathologic nodal staging of resected lung cancerR01CA172253 · NCI · UNIVERSITY OF MEMPHIS · PI OSAROGIAGBON, RAYMOND U · 2013 to 2022
$4.8M
NCI NIH HHS R01 CA172253
6 · The paper itself

Abstract

Accurate post-operative prognostication and management heavily depend on pathologic nodal stage. Patients with nodal metastasis benefit from post-operative adjuvant chemotherapy, those with mediastinal nodal involvement may also benefit from adjuvant radiation therapy. However, the quality of pathologic nodal staging varies significantly, with major survival implications in large populations of patients. We describe the quality gap in pathologic nodal staging, and provide evidence of its potential reversibility by targeted corrective interventions. One intervention, designed to improve the surgical lymphadenectomy, specimen labeling, and secure transfer between the operating theatre and the pathology laboratory, involves use of pre-labeled specimen collection kits. Another intervention involves application of an improved method of gross dissection of lung resection specimens, to reduce the inadvertent loss of intrapulmonary lymph nodes to histologic examination for metastasis. These corrective interventions are the subject of a regional dissemination and implementation project in diverse healthcare systems in a tri-state region of the United States with some of the highest lung cancer incidence and mortality rates. We discuss the potential of these interventions to significantly improve the accuracy of pathologic nodal staging, risk stratification, and the quality of specimens available for development of stage-independent prognostic markers in lung cancer.

Indexed as

lung cancer surgerynodal stagingQuality of caresurvival

Identifiers

PMID26380184
PMCPMC4549477
OpenAlexW2176136195

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.